R C Shah1, A S Buchman, R S Wilson, S E Leurgans, D A Bennett. 1. Rush Alzheimer's Disease Center, Rush University Medical Center, Armour Academic Facility, Suite 1038, 600 South Paulina St., Chicago, IL 60612, USA. Raj_C_Shah@rush.edu
Abstract
OBJECTIVE: To test the hypothesis that level of hemoglobin is associated with incident Alzheimer disease (AD). METHODS: A total of 881 community-dwelling older persons participating in the Rush Memory and Aging Project without dementia and a measure of hemoglobin level underwent annual cognitive assessments and clinical evaluations for AD. RESULTS: During an average of 3.3 years of follow-up, 113 persons developed AD. In a Cox proportional hazards model adjusted for age, sex, and education, there was a nonlinear relationship between baseline level of hemoglobin such that higher and lower levels of hemoglobin were associated with AD risk (hazard ratio [HR] for the quadratic of hemoglobin 1.06, 95% confidence interval [CI] 1.01-1.11). Findings were unchanged after controlling for multiple covariates. When compared to participants with clinically normal hemoglobin (n = 717), participants with anemia (n = 154) had a 60% increased hazard for developing AD (95% CI 1.02-2.52), as did participants with clinically high hemoglobin (n = 10, HR 3.39, 95% CI 1.25-9.20). Linear mixed-effects models showed that lower and higher hemoglobin levels were associated with a greater rate of global cognitive decline (parameter estimate for quadratic of hemoglobin = -0.008, SE -0.002, p < 0.001). Compared to participants with clinically normal hemoglobin, participants with anemia had a -0.061 z score unit annual decline in global cognitive function (SE 0.012, p < 0.001), as did participants with clinically high hemoglobin (-0.090 unit/year, SE 0.038, p = 0.018). CONCLUSIONS: In older persons without dementia, both lower and higher hemoglobin levels are associated with an increased hazard for developing AD and more rapid cognitive decline.
OBJECTIVE: To test the hypothesis that level of hemoglobin is associated with incident Alzheimer disease (AD). METHODS: A total of 881 community-dwelling older persons participating in the Rush Memory and Aging Project without dementia and a measure of hemoglobin level underwent annual cognitive assessments and clinical evaluations for AD. RESULTS: During an average of 3.3 years of follow-up, 113 persons developed AD. In a Cox proportional hazards model adjusted for age, sex, and education, there was a nonlinear relationship between baseline level of hemoglobin such that higher and lower levels of hemoglobin were associated with AD risk (hazard ratio [HR] for the quadratic of hemoglobin 1.06, 95% confidence interval [CI] 1.01-1.11). Findings were unchanged after controlling for multiple covariates. When compared to participants with clinically normal hemoglobin (n = 717), participants with anemia (n = 154) had a 60% increased hazard for developing AD (95% CI 1.02-2.52), as did participants with clinically high hemoglobin (n = 10, HR 3.39, 95% CI 1.25-9.20). Linear mixed-effects models showed that lower and higher hemoglobin levels were associated with a greater rate of global cognitive decline (parameter estimate for quadratic of hemoglobin = -0.008, SE -0.002, p < 0.001). Compared to participants with clinically normal hemoglobin, participants with anemia had a -0.061 z score unit annual decline in global cognitive function (SE 0.012, p < 0.001), as did participants with clinically high hemoglobin (-0.090 unit/year, SE 0.038, p = 0.018). CONCLUSIONS: In older persons without dementia, both lower and higher hemoglobin levels are associated with an increased hazard for developing AD and more rapid cognitive decline.
Authors: Aron S Buchman; Patricia A Boyle; Robert S Wilson; Todd L Beck; Jeremiah F Kelly; David A Bennett Journal: Alzheimer Dis Assoc Disord Date: 2009 Jan-Mar Impact factor: 2.703
Authors: Robert S Wilson; Carlos F Mendes De Leon; Lisa L Barnes; Julie A Schneider; Julia L Bienias; Denis A Evans; David A Bennett Journal: JAMA Date: 2002-02-13 Impact factor: 56.272
Authors: Jack M Guralnik; Richard S Eisenstaedt; Luigi Ferrucci; Harvey G Klein; Richard C Woodman Journal: Blood Date: 2004-07-06 Impact factor: 22.113
Authors: Jacob R Hascalovici; Jacob Vaya; Soliman Khatib; Christina A Holcroft; Hillel Zukor; Wei Song; Zoe Arvanitakis; David A Bennett; Hyman M Schipper Journal: J Neurochem Date: 2009-06-09 Impact factor: 5.372
Authors: David A Bennett; Julie A Schneider; Aron S Buchman; Lisa L Barnes; Patricia A Boyle; Robert S Wilson Journal: Curr Alzheimer Res Date: 2012-07 Impact factor: 3.498
Authors: N G Faux; A Rembach; J Wiley; K A Ellis; D Ames; C J Fowler; R N Martins; K K Pertile; R L Rumble; B Trounson; C L Masters; A I Bush Journal: Mol Psychiatry Date: 2014-01-14 Impact factor: 15.992
Authors: May A Beydoun; Sharmin Hossain; Hind A Beydoun; Danielle Shaked; Jordan Weiss; Michele K Evans; Alan B Zonderman Journal: J Nutr Date: 2020-01-01 Impact factor: 4.798
Authors: Andrea L C Schneider; Charles Jonassaint; A Richey Sharrett; Thomas H Mosley; Brad C Astor; Elizabeth Selvin; Josef Coresh; Rebecca F Gottesman Journal: J Gerontol A Biol Sci Med Sci Date: 2015-09-11 Impact factor: 6.053
Authors: Jennifer Weuve; Carlos F Mendes de Leon; David A Bennett; Xinqi Dong; Denis A Evans Journal: Alzheimer Dis Assoc Disord Date: 2014 Apr-Jun Impact factor: 2.703
Authors: David A Bennett; Aron S Buchman; Patricia A Boyle; Lisa L Barnes; Robert S Wilson; Julie A Schneider Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472